Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    MK-6096
Show Display Options
Rank Status Study
1 Completed A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)
Conditions: Migraine;   Headache
Interventions: Drug: MK-6096;   Drug: Placebo
2 Terminated Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
Condition: Major Depressive Disorder, Recurrent
Interventions: Drug: MK-6096;   Drug: Placebo
3 Completed Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)
Condition: Diabetic Neuropathy, Painful
Interventions: Drug: MK-6096;   Drug: Placebo
4 Completed Polysomnography Study of MK6096 in Patients With Primary Insomnia (6096-011)
Condition: Primary Insomnia
Interventions: Drug: MK6096 2.5 mg and placebo;   Drug: Comparator: MK6096 5 mg and placebo;   Drug: Comparator: MK6096 10 mg and placebo;   Drug: Comparator: MK6096 20 mg and placebo

Indicates status has not been verified in more than two years